INVANasdaqPharmaceutical PreparationsFiscal year ends December 31

Innoviva, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$21.08+0.30 (+1.44%)

Close on Oct 19, 2026

Market cap: $1.55B
P/E (TTM): 5.2
Dividend yield: –

Innoviva, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	411	359	310	331	392	337	261	261	217	134	54	8.43	4.53	5.61	25	24	24
Gross Profit	308	296	246	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Research & Development	31	14	34	41	0.58	1.79	0	0	1.36	1.39	2.62	7.50	9.04	8.15	104	75	78
Selling, General & Admin	113	116	98	64	16	14	–	–	–	–	–	–	48	31	31	–	–
General & Administrative	–	–	–	–	16	14	15	20	32	23	20	35	24	23	31	27	27
Advertising Expenses	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	–	–
Operating Expenses	144	129	132	–	17	16	15	23	34	25	22	42	33	31	134	103	106
Total Costs & Expenses	–	321	116	44	-53	-17	–	–	–	–	–	–	–	–	–	–	–
Operating Income	164	167	114	–	375	321	246	238	184	109	32	-34	-29	-25	-110	-78	-81
Interest Expense	17	22	19	16	19	18	19	24	44	52	52	37	9.35	6.00	6.02	6.04	6.05
Income from Equity Investments	141	-64	77	-162	84	50	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-2.86	-3.00	-4.97	-3.37	-3.63	-0.35	-0.35	-5.70	-7.04	2.48	1.12	-3.27	6.73	0	0	–	–
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1.15
Asset Impairment Charges	0	0	0	–	–	–	–	–	–	–	–	–	–	0.20	–	–	–
Gain (Loss) on Investments	–	–	–	–	91	50	0	0	0	0	1.22	0	0	0.01	0.00	0.00	–
Gain (Loss) on Sale of Assets	–	–	–	–	0	0	-0.10	0	0	–	–	–	–	-0.20	–	-0.03	–
Pretax Income	327	37	194	287	445	354	233	210	134	60	-19	-74	-31	–	–	–	–
Income Tax Expense	56	14	14	67	76	60	42	-196	0.00	0.10	0	0	0	0	0	–	–
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	-19	-74	-31	-31	–	–	–
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	0	0	-95	-140	12	–	–	–
Net Income incl. Noncontrolling Interests	271	23	180	220	369	294	191	406	134	60	-19	–	–	–	–	–	–
Minority Interest in Earnings	–	0	0	6.34	103	69	34	11	0.13	0	0	–	–	–	–	–	–
Net Income to Common	271	23	180	214	266	224	157	395	134	60	-19	-168	-171	-19	-115	-84	-85
EPS (Basic)(per share)	4.02	0.37	2.75	3.07	3.24	2.21	1.55	3.92	1.25	0.54	-0.16	-1.50	-1.67	-0.20	-1.41	-1.16	-1.35
EPS (Diluted)(per share)	3.30	0.36	2.20	2.37	2.87	2.02	1.43	3.53	1.17	0.53	-0.16	-1.50	-1.67	-0.20	-1.41	-1.16	-1.35
Shares Outstanding (Basic, Weighted)(shares)	67	63	65	70	82	101	101	101	107	110	115	112	102	91	82	72	63
Shares Outstanding (Diluted, Weighted)(shares)	85	74	87	95	94	114	113	113	120	123	115	112	102	91	82	72	63
Dividend per Share(per share)	–	–	–	–	–	–	–	–	0.00	0.00	0.75	0.50	0.00	0.00	–	–	–
EBITDA	–	–	–	–	389	335	260	252	198	123	46	-22	-25	-22	-102	-72	-76
Total Interest Income	21	19	16	6.37	1.84	1.52	5.54	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 72.2%
Operating margin: 36.9%
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 16.01
Debt to equity: 0.21
Debt to assets: 15.2%
Cash to current liabilities: 1211.9%

Valuation

P/E ratio: 5.2
Price to sales: 3.52
Price to book: 1.25
Dividend yield: –